Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Jonathan A. Ledermann(CRUK Lung Cancer Centre of Excellence), Philipp Harter(Kliniken Essen-Mitte), Charlie Gourley(MRC Institute of Genetics and Molecular Medicine), Michael Friedländer(UNSW Sydney), Ignace Vergote(KU Leuven), Gordon Rustin(Mount Vernon Hospital), Clare L. Scott(The Royal Melbourne Hospital), Werner Meier(Evangelisches Krankenhaus Düsseldorf), Ronnie Shapira‐Frommer(Sheba Medical Center), Tamar Safra(Tel Aviv Sourasky Medical Center), Daniela Matei(Indiana University – Purdue University Indianapolis), Anitra Fielding(AstraZeneca (United Kingdom)), Stuart Spencer(AstraZeneca (United Kingdom)), Brian Dougherty(AstraZeneca (United States)), Maria Orr(AstraZeneca (United Kingdom)), Darren Hodgson(AstraZeneca (United Kingdom)), J. Carl Barrett(AstraZeneca (United States)), Ursula A. Matulonis(Dana-Farber Cancer Institute)
Cited by 1,441
Abstract
Related Papers
No related papers found
Powered by citation graph analysis